Institution
Beatson West of Scotland Cancer Centre
Healthcare•Glasgow, Scotland, United Kingdom•
About: Beatson West of Scotland Cancer Centre is a healthcare organization based out in Glasgow, Scotland, United Kingdom. It is known for research contribution in the topics: Cancer & Population. The organization has 489 authors who have published 1031 publications receiving 41277 citations. The organization is also known as: Beatson Oncology Centre.
Topics: Cancer, Population, Gemcitabine, Prostate cancer, Radiation therapy
Papers
More filters
••
TL;DR: Parenteral oestrogen could be a potential alternative to LHRHa in management of prostate cancer if efficacy is confirmed, and enrolment in the PATCH trial has been extended, with a primary outcome of progression-free survival.
Abstract: Summary Background Luteinising-hormone-releasing-hormone agonists (LHRHa) to treat prostate cancer are associated with long-term toxic effects, including osteoporosis. Use of parenteral oestrogen could avoid the long-term complications associated with LHRHa and the thromboembolic complications associated with oral oestrogen. Methods In this multicentre, open-label, randomised, phase 2 trial, we enrolled men with locally advanced or metastatic prostate cancer scheduled to start indefinite hormone therapy. Randomisation was by minimisation, in a 2:1 ratio, to four self-administered oestrogen patches (100 μg per 24 h) changed twice weekly or LHRHa given according to local practice. After castrate testosterone concentrations were reached (1·7 nmol/L or lower) men received three oestrogen patches changed twice weekly. The primary outcome, cardiovascular morbidity and mortality, was analysed by modified intention to treat and by therapy at the time of the event to account for treatment crossover in cases of disease progression. This study is registered with ClinicalTrials.gov, number NCT00303784. Findings 85 patients were randomly assigned to receive LHRHa and 169 to receive oestrogen patches. All 85 patients started LHRHa, and 168 started oestrogen patches. At 3 months, 70 (93%) of 75 receiving LHRHa and 111 (92%) of 121 receiving oestrogen had achieved castrate testosterone concentrations. After a median follow-up of 19 months (IQR 12–31), 24 cardiovascular events were reported, six events in six (7·1%) men in the LHRHa group (95% CI 2·7–14·9) and 18 events in 17 (10·1%) men in the oestrogen-patch group (6·0–15·6). Nine (50%) of 18 events in the oestrogen group occurred after crossover to LHRHa. Mean 12-month changes in fasting glucose concentrations were 0·33 mmol/L (5·5%) in the LHRHa group and −0·16 mmol/L (−2·4%) in the oestrogen-patch group (p=0·004), and for fasting cholesterol were 0·20 mmol/L (4·1%) and −0·23 mmol/L (−3·3%), respectively (p vs 104 [75%] of 138 in the oestrogen-patch group), hot flushes (44 [56%] vs 35 [25%]), and dermatological problems (10 [13%] vs 58 [42%]). Interpretation Parenteral oestrogen could be a potential alternative to LHRHa in management of prostate cancer if efficacy is confirmed. On the basis of our findings, enrolment in the PATCH trial has been extended, with a primary outcome of progression-free survival. Funding Cancer Research UK, MRC Clinical Trials Unit.
84 citations
••
National Taiwan University1, University of California, Los Angeles2, Yonsei University3, California Pacific Medical Center4, Fourth Military Medical University5, Gdańsk Medical University6, Hannover Medical School7, Russian Academy8, Beatson West of Scotland Cancer Centre9, Eisai10, Kindai University11
TL;DR: A phase III trial of LEN vs SOR as first-line therapy for uHCC, with primary endpoint overall survival and secondary efficacy endpoints progression-free survival, time to progression (TTP) and objective response rate (ORR) by mod...
Abstract: 4001Background: SOR is the only approved agent in uHCC and new options are needed. LEN, an inhibitor of vascular endothelial growth factor receptors 1‒3, fibroblast growth factor receptors 1‒4, platelet derived growth factor receptor α, RET, and KIT, showed activity in uHCC in a phase II trial. We report a phase III trial of LEN vs SOR as first-line therapy for uHCC. Methods: In this randomized, open-label, noninferiority (NI) study, pts had uHCC, ≥ 1 measurable target lesion, Barcelona Clinic Liver Cancer stage B or C, Child-Pugh class A, ECOG PS ≤ 1, and no prior systemic therapy. Pts were randomized 1:1 to LEN (body weight ≥ 60 kg: 12 mg/day; < 60 kg: 8 mg/day) or SOR 400 mg twice daily. The primary endpoint was overall survival (OS). The OS hazard ratio (HR) and its 95% CI were estimated with a stratified Cox proportional hazard model. The predefined NI margin was 1.08. Secondary efficacy endpoints were progression-free survival (PFS), time to progression (TTP) and objective response rate (ORR) by mod...
82 citations
••
TL;DR: In this article, the authors explored the feasibility and acceptability of the advanced symptom management system with patients with lung cancer receiving radiotherapy and clinicians involved in their care and assessed changes in patient outcomes during implementation of the Advanced Symptom Management System.
Abstract: BACKGROUND: The use of technology-enhanced patient-reported outcome measures to monitor the symptoms experienced by people with cancer is an effective way to offer timely care. OBJECTIVE: This study aimed to (a) explore the feasibility and acceptability of the Advanced Symptom Management System with patients with lung cancer receiving radiotherapy and clinicians involved in their care and (b) assess changes in patient outcomes during implementation of the Advanced Symptom Management System with patients with lung cancer receiving radiotherapy in clinical practice. METHODS: A repeated-measures, single-arm, mixed-methods study design was used involving poststudy interviews and completion of patient-reported outcome measures at baseline and end of treatment with 16 patients with lung cancer and 13 clinicians who used this mobile phone-based symptom monitoring system. RESULTS: Only rarely did patients report problems in using the handset and they felt that the system covered all relevant symptoms and helped them to manage their symptoms and effectively communicate with clinicians. Clinical improvements in patient anxiety, drowsiness, and self-care self-efficacy were also observed. Clinicians perceived the use of "real-time" risk algorithms and automated self-care advice provided to patients as positively contributing to clinical care. Reducing the complexity of the system was seen as important to promote its utility. CONCLUSIONS: Although preliminary, these results suggest that monitoring patient symptoms using mobile technology in the context of radiotherapy for lung cancer is feasible and acceptable in clinical practice. IMPLICATIONS FOR PRACTICE: Future research would be most beneficial if the use of this technology was focused on the postradiotherapy phase and expanded the scope of the system to encompass a wider range of supportive care needs.
82 citations
••
TL;DR: The addition of pertuzumab to trastuzumAB and capecitabine did not significantly improve independent review facility-assessed progression-free survival (IRF PFS).
Abstract: Purpose To assess the efficacy and safety of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy and received a prior taxane. Patients and Methods Patients were randomly assigned to arm A: trastuzumab 8 mg/kg → 6 mg/kg once every 3 weeks plus capecitabine 1,250 mg/m2 twice a day (2 weeks on, 1 week off, every 3 weeks); or arm B: pertuzumab 840 mg → 420 mg once every 3 weeks plus trastuzumab at the same dose and schedule as arm A plus capecitabine 1,000 mg/m2 on the same schedule as arm A. The primary end point was independent review facility-assessed progression-free survival (IRF PFS). Secondary end points included overall survival (OS) and safety. Hierarchical testing procedures were used to control type I error for statistical testing of IRF PFS, OS, and objective response rate. Results Randomly assigned (intent-to-treat) populations were 224 and 228 patients in arms A and B, respectively. Median IRF PFS at 28.6 and 25.3 months' median follow-up was 9.0 v 11.1 months (hazard ratio, 0.82; 95% CI, 0.65 to 1.02; P = .0731) and interim OS was 28.1 v 36.1 months (hazard ratio, 0.68; 95% CI, 0.51 to 0.90). The most common adverse events (all grades; incidence of ≥ 10% in either arm and ≥ 5% difference between arms) were hand-foot syndrome, nausea, and neutropenia in arm A, and diarrhea, rash, and nasopharyngitis in arm B. Conclusion The addition of pertuzumab to trastuzumab and capecitabine did not significantly improve IRF PFS. An 8-month increase in median OS to 36.1 months with pertuzumab was observed. Statistical significance for OS cannot be claimed because of the hierarchical testing of OS after the primary PFS end point; however, the magnitude of OS difference is in keeping with prior experience of pertuzumab in metastatic breast cancer. No new safety signals were identified.
81 citations
••
Memorial Sloan Kettering Cancer Center1, Sarah Cannon Research Institute2, Yale Cancer Center3, University of Texas MD Anderson Cancer Center4, Harvard University5, University of Helsinki6, Beatson West of Scotland Cancer Centre7, The Royal Marsden NHS Foundation Trust8, Bristol-Myers Squibb9, Johns Hopkins University10
TL;DR: Results are reported of a completed A/M GC cohort of CheckMate-032 study evaluating nivo monotherapy and nivo with ipi in pts with solid tumors, and baseline characteristics were comparable across cohorts.
Abstract: 4010Background: Chemotherapy-refractory GC is a uniformly fatal illness and an unmet therapeutic need. Nivo is a fully human anti-PD-1 monoclonal antibody with a manageable safety profile and efficacy in solid tumors. We report results of a completed A/M GC cohort of CheckMate-032 study evaluating nivo monotherapy and nivo with ipi in pts with solid tumors. Methods: Pts with A/M, histologically confirmed GC, esophageal (EC), or gastroesophageal junction cancer (GEC), irrespective of PD-L1 status, who had progressed on chemotherapy, were treated with nivo 3 mg/kg Q2W (N3), nivo 1 mg/kg + ipi 3 mg/kg (N1+I3), or nivo 3 mg/kg + ipi 1 mg/kg (N3+I1) Q3W x 4 cycles, followed by nivo 3 mg/kg Q2W until confirmed disease progression or intolerable toxicity. Primary endpoint was ORR; other endpoints included safety, OS, and biomarker status. Results: 160 pts with A/M GC were treated with N3 (n = 59), N1+I3 (n = 49), or N3+I1 (n = 52). Baseline characteristics were comparable across cohorts; the majority of pts had ...
81 citations
Authors
Showing all 491 results
Name | H-index | Papers | Citations |
---|---|---|---|
Stan B. Kaye | 92 | 449 | 35666 |
Tessa L. Holyoake | 65 | 272 | 18780 |
Jim Cassidy | 64 | 217 | 20828 |
John Bellamy Foster | 59 | 531 | 15649 |
James Paul | 59 | 252 | 13394 |
Hani Gabra | 53 | 200 | 23073 |
Iain A. McNeish | 52 | 228 | 17880 |
Richard H. Wilson | 50 | 188 | 8989 |
David K. Chang | 48 | 126 | 14460 |
Thomas J. Evans | 48 | 143 | 13144 |
Robert Jones | 46 | 262 | 16459 |
Nigel B. Jamieson | 44 | 131 | 10913 |
T.R. Jeffry Evans | 41 | 113 | 7283 |
Anthony J. Chalmers | 35 | 133 | 4254 |
Mhairi Copland | 33 | 121 | 4795 |